Previous Close | 2.2500 |
Open | N/A |
Bid | 2.3500 |
Ask | 4.2000 |
Strike | 12.50 |
Expire Date | 2024-05-17 |
Day's Range | 2.2500 - 2.2500 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.